<DOC>
	<DOCNO>NCT00413439</DOCNO>
	<brief_summary>Patients undergo chemotherapy leukemia receive study medication prevention fungal infection . The study investigate safety tolerability two different dosage , efficacy prevention fungal disease .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics Antifungal Patients Undergoing Chemotherapy</brief_title>
	<detailed_description>Patients Acute Myeloid Leukemia undergo aggressive chemotherapy due immunosuppression susceptible infection , include fungal infection . As failure rate treatment invasive fungal infection high , prophylaxis frequently recommend . This open label study investigate safety tolerability two different dosage water soluble azole antifungal , well efficacy prevention invasive fungal infection pharmacokinetic data .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>diagnosis acute myeloid leukemia patient enter first induction treatment ; subsequent chemotherapy prior invasive fungal infection observe expect neutropenic &gt; 9 &lt; 28 day enrollment woman childbearing potential must negative pregnancy test patient receive systemic antifungal therapy 72 hour prior first administration study medication . Topical polyenes nystatin acceptable discontinue study patient receive systemic antifungal therapy proven probable fungal infection last 12 month patient fever defined central body temperature &gt; 38Â°C know hypersensitivity azoles component study medication concomitant use rifampicin , rifabutin , ergots alkaloid , terfenadine , astemizole , cisapride , pimozide , quinidine , long act barbiturate , neostigmine , carbamazepine hepatic severe renal dysfunction patient medical history oliguria unresponsive fluid challenge patient concomitant medical condition may unacceptable additional risk patient he/she participate study treatment investigational drug within 30 day prior first administration study medication except open label chemotherapy protocol suspect additional cause neutropenia immunosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>BAL8557</keyword>
	<keyword>ASP9766</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>systemic fungal infection</keyword>
</DOC>